fbpx

molecules of the month

PF-06939999

oral SAM-competitive PRMT5 inhibitor

Ph. I candidate for solid tumors (adv. or met.)

SBDD utilizing PRMT5:MEP50 w/ A9145C

Molecular Cancer Therapy

Pfizer Oncology

Chemical structure of molecule PF-06939999 Pfizer SAM-competitive PRMT5 inhibitor
1 min read

10.   The Pfizer SAM-competitive PRMT5 inhibitor, PF-06939999 is a Ph. I clinical candidate in dose escalation in solid tumors. Ph. I data has been reported showing signs of early efficacy with cytopenias as common adverse events. This is in agreement with Ph. I data that was recently reported for a JNJ SAM-competitive PRMT5 inhibitor in which thrombocytopenia was identified as a dose-limiting toxicity and an early efficacy signal may have been detected. The Pfizer team suggests that PRMT5i may be especially beneficial in cancers which are dependent on alternative splicing pathways. Furthermore, preclinical resistance studies suggest that complete resistance to SAM site inhibitors may be prevented due to structural constraints in the co-factor binding site. The discovery campaign began with the published crystal structure of PRMT5:MEP50…


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: